REGN 7508
Alternative Names: REGN-7508; REGN-7508CatLatest Information Update: 04 Apr 2026
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antiarrhythmics; Antithrombotics; Monoclonal antibodies
- Mechanism of Action Factor XI inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Thrombosis; Venous thromboembolism
- Phase II Atrial fibrillation
Most Recent Events
- 04 Apr 2026 REGN 7508 is still in phase I development for Thrombosis(In volunteers) in United Kingdom (IV)
- 04 Apr 2026 REGN 7508 is still in phase I development for Thrombosis(In volunteers) in United Kingdom (SC)
- 27 Mar 2026 Regeneron Pharmaceuticals completes the phase II ROXI-CATH trial in Venous thromboembolism (Prevention) in USA, UK, Canada, Bulgaria, Romania, Israel (IV) (NCT06299111)